ArticlePloS one2026
RETRACTED: NFIC suppressed the development of Glioma via modulating the balance of SHP2/PI3K and NF-κB/PTEN Signaling.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
- Retraction · 2026-05-27Concerns/Issues about Article · Concerns/Issues about Results and/or Conclusions · Objections by Author(s) ·
- Retracted
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe objective of this study is to elucidate the mechanism by which NFIC exerts its regulatory influence over NF-κB/PTEN, with a view to gaining insight into the processes underlying the proliferation and invasion of glioma cells.
methodsThe interactions between genes in gliomas were predicted and verified through bioinformatics analysis. The effect of NFIC on glioma development was detected via subcutaneous transplantation in nude mice. Protein expression levels of NFIC, OGN, NF-κB, SHP2, p-SHP2, PI3K, AKT, Cyclin A1, Cyclin D1, MMP-3, and MMP-9 were detected by western blot. The examination of tumour cell proliferation and invasion was conducted using the following assays: CCK-8, colony formation, scratch assay, Co-immunoprecipitation (Co-IP) experiment, Immunohistochemistry (IHC) experiment and Transwell.
resultsNFIC binds to the promoter regions of OGN and PTEN and regulates their transcription, leading to increased expression of these two genes,while simultaneously limiting the expression of NF-κB, SHP2, p-SHP2, PI3K, AKT, Cyclin A1, Cyclin D1, MMP-3, and MMP-9. NF-κB promotes SHP2 expression, whereas OGN and PTEN inhibit p-SHP2 expression. NFIC inhibits the proliferation and invasion of glioma cells, while NF-κB promotes these processes.
conclusionThe overexpression of NFIC has the capacity to inhibit the PI3K/AKT signalling pathway, a process facilitated by the promotion of the expression of OGN and PTEN. This, consequently, results in the inhibition of glioma proliferation and development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.